Details about Christopher James Sampson
Access statistics for papers by Christopher James Sampson.
Last updated 2024-09-09. Update your information in the RePEc Author Service.
Short-id: psa1048
Jump to Journal Articles
Working Papers
2023
- The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe
Contract Research, Office of Health Economics
2021
- How is Quality of Life Measured for Health Technology Assessments?
Briefing, Office of Health Economics
2020
- Drop Dead: Is Anchoring at ‘Dead’ a Theoretical Requirement in Health State Valuation?
Grant-Funded Research, Office of Health Economics
2019
- How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy
Briefing, Office of Health Economics View citations (3)
2018
- Barriers to Uptake of Minimal Access Surgery in the United Kingdom
Contract Research, Office of Health Economics
- R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
Grant-Funded Research, Office of Health Economics View citations (1)
- The Impact of New Medicines in the NHS: 70 Years of Innovation
Contract Research, Office of Health Economics
2013
- Cost implications of treatment non-completion in a forensic personality disorder service
MPRA Paper, University Library of Munich, Germany
- Happy and healthy: a joint model of health and life satisfaction
MPRA Paper, University Library of Munich, Germany
- The relationship between individual risk and cost-effectiveness in screening interventions
MPRA Paper, University Library of Munich, Germany
Journal Articles
2024
- Is anchoring at ‘dead’ a theoretical requirement for health state valuation?
Health Economics, 2024, 33, (9), 1929-1935
- Marginal cost per QALY estimates: What are they good for?
Health Policy, 2024, 142, (C)
2022
- NICE and the EQ-5D-5L: Ten Years Trouble
PharmacoEconomics - Open, 2022, 6, (1), 5-8
- Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy
Applied Health Economics and Health Policy, 2022, 20, (5), 651-667 View citations (1)
2021
- Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al
Medical Decision Making, 2021, 41, (3), 255-257 View citations (1)
2019
- Transparency in Decision Modelling: What, Why, Who and How?
PharmacoEconomics, 2019, 37, (11), 1355-1369 View citations (3)
2017
- Model Registration: A Call to Action
PharmacoEconomics - Open, 2017, 1, (2), 73-77 View citations (4)
2013
- Do patients registered with CAM-trained GPs really use fewer health care resources and live longer? A response to Kooreman and Baars. Eur J Health Econ (2012). 13:469–776
The European Journal of Health Economics, 2013, 14, (4), 703-705
|
The links between different versions of a paper are constructed automatically by matching on the titles.
Please contact if a link is incorrect.
Use this form
to add links between versions where the titles do not match.
|